C4 Therapeutics, Inc. · NASDAQ:CCCC

C4 Therapeutics — Investor Presentation (January 2024)

31 slides from C4 Therapeutics's investor presentation, Jan 11, 2024

  1. Slide 1: Protein degraded. Disease targeted. Lives transformed.

    January 2024 Protein degraded. Disease targeted. Lives transformed.

  2. Slide 2: Forward-looking Statements and Intellectual Property

    Forward-looking Statements and Intellectual Property 2 Forward-looking Statements The following presentation contains forward-looking statements. All statements other than statements of historical fact are forward- looking statements, which are often indicated by terms such as “anticipate,” “believe

  3. Slide 3: C4T is a Recognized Leader in Delivering on the Promise of Targeted Protein Degradation

    C4T is a Recognized Leader in Delivering on the Promise of Targeted Protein Degradation 3 WORLD-CLASS DEGRADER PLATFORM Robust patent portfolio of novel cereblon binders; Demonstrated ability to design orally bioavailable, catalytically efficient degraders Our Mission To deliver on the promise of ta

  4. Slide 4: We Have Designed and Advanced Degraders into the Clinic across a Range of Target Classes

    We Have Designed and Advanced Degraders into the Clinic across a Range of Target Classes, Resulting in Robust Target Degradation © 2024 C4 Therapeutics, Inc. Degraded Target as Predicted Interrogated Diverse Target Classes Attained IND Clearance Achieved Desirable Drug-like Properties 1. Evaluated t

  5. Slide 5: Prioritized Pipeline to Deliver Near-Term Value

    Undisclosed Discovery Stage Programs Various Cancers Undisclosed Collaboration Programs Autoimmune & Cancer Autoimmune & Neurological Cancer Prioritized Pipeline to Deliver Near-Term Value © 2024 C4 Therapeutics, Inc. Program Target Indications CFT7455 IKZF1/3 Multiple Myeloma & Non-Hodgkin’s Lympho

  6. Slide 6: Capital from ATM, Betta Equity, and Merck Upfront Extends Cash Runway into 2027

    Capital1 from ATM, Betta Equity, and Merck Upfront Combined with Cost Savings from Restructuring Extends Cash Runway into 2027 2023 Accomplishments Position C4T for Future Value Creation © 2024 C4 Therapeutics, Inc. ✓ Presented positive CFT7455 Phase 1 dose escalation data in R/R MM demonstrating ne

  7. Slide 7: 2024 Milestones: Advancing High-potential Programs

    2024 Milestones: Advancing High-potential Programs © 2024 C4 Therapeutics, Inc. 7 Multiple Value Inflection Points over Next 12 Months with Sufficient Runway (into 20271) Beyond These Milestones CFT7455 IKZF1/3 • 2H 2024: Present updated data from Phase 1 dose escalation +dex trial in R/R MM • 2H 20

  8. Slide 8: CFT7455 Targeting IKZF1/3 Multiple Myeloma & Non-Hodgkin's Lymphoma

    CFT7455 Targeting IKZF1/3 Multiple Myeloma (MM) & Non-Hodgkin’s Lymphoma (NHL)

  9. Slide 9: IKZF1/3 Degradation Drives Three Distinct Areas of Hematopoietic Biology

    IKZF1/3 Degradation Drives Three Distinct Areas of Hematopoietic Biology; Degrading IKZF1/3 is a Validated Therapeutic Strategy in MM and NHL Ikaros Family Zinc Finger proteins 1 and 3 (IKZF1/3); Multiple Myeloma (MM); Non-Hodgkin’s Lymphoma (NHL) © 2024 C4 Therapeutics, Inc IKZF1 / IKZF3 Transcript

  10. Slide 10: CFT7455 Phase 1 Dose Escalation Trial Design

    R/R MM Monotherapy Dosing: QD 21 days on/7 days off N=5 Status: Complete CFT7455 Phase 1 Dose Escalation Trial’s Goal is to Define the Safety Profile and Identify Signs of Anti-Tumor Activity in R/R MM and R/R NHL Pharmacokinetic (PK); Monday, Wednesday, Friday dosing (MWF); once daily (QD); Relapse

  11. Slide 11: Schedule Adjustment Yielding Expected Results for CFT7455 as a Potential MM Therapy

    Schedule Adjustment Yielding Expected Results for CFT7455 as a Potential MM Therapy © 2024 C4 Therapeutics, Inc. Established Safety Profile and Dosing Schedule • CFT7455 is well tolerated with no DLTs resulting in treatment discontinuations • The 14 days on/14 days off schedule is optimal Demonstrat

  12. Slide 12: CFT7455 Monotherapy Pharmacodynamics Consistent with 14 Days On/14 Days Off Modeling

    CFT7455 Monotherapy Pharmacodynamics Consistent with 14 Days On/14 Days Off Modeling; Schedule is Sufficient for Neutrophil Recovery Daily dosing (QD); Pharmacokinetic (PK); Pharmacodynamic (PD); Monday, Wednesday, Friday dosing (MWF) Source: C4T data on file as of 11/28/23 © 2024 C4 Therapeutics, I

  13. Slide 13: CFT7455 Monotherapy Data Support Opportunity for Combination with Novel MM Agents

    CFT7455 Monotherapy Data Support Opportunity for Combination with Novel MM Agents © 2024 C4 Therapeutics, Inc. 13 Evidence of Anti-Myeloma Monotherapy Activity 20 patients were efficacy evaluable and in total, achieved: • 1 partial response • 2 minimal responses • 9 stable disease All 4 patients at

  14. Slide 14: Clinical Evidence of Immune T-cell Activation with CFT7455 Monotherapy

    TEMRA TEM 0 20 40 60 80 100 % positive cells (C1D21 vs C1D1) % p o s it iv e c e ll s C1D1 C1D21 © 2024 C4 Therapeutics, Inc. Clinical Evidence of Immune T-cell Activation with CFT7455 Monotherapy ** **** TEMRA: Terminally differentiated T-cells TEM: Effector memory T-cells Peripheral Blood Mononucl

  15. Slide 15: CFT7455 Combined with Novel MM Agents Demonstrates Enhanced Immune Cell Lysis

    CFT7455 Combined with Novel MM Agents Demonstrates Enhanced Immune Cell Lysis in Non-clinical Translational Models Bispecific T-Cell Engager (BiTE) Source: C4T data on file as of 11/28/2023 Cmin and Cmax represent human plasma concentrations for a 50 µg dose of CFT7455 Daratumumab (Anti-CD38) Combo

  16. Slide 16: CFT7455 + Dexamethasone Dose Escalation in R/R MM Continues to Progress

    Potential for further dose escalation CFT7455: 62.5 µg QD +dex: 40 mg QW* N= ~4 Currently enrolling CFT7455: 37.5 µg QD +dex: 40 mg QW* N=4 CFT7455: 50 µg; MWF +dex: 40 mg QW* N=5 CFT7455 + Dexamethasone Dose Escalation in R/R MM Continues to Progress © 2024 C4 Therapeutics, Inc. Phase 1: Dose Escal

  17. Slide 17: CFT7455 + Dexamethasone is Well Tolerated with Best Responses in BCMA-Refractory Patients

    Dosing Schedule Dose Level EMD Status Prior CAR-T or TCE # of Prior Lines Cycle 1 Cycle 2 Cycle 3 Cycle 4 Cycle 5 Cycle 6 Cycle 7 Cycle 8 Cycle 9 Cycle 10 Cycle 11 14 days on/ 14 days off CFT7455: 50 µg MWF +dex: 40 mg QW No No 6 PD No Yes 4 SD PD No No 5 SD MR PR Yes Yes 12 PD No No 6 SD CFT7455: 3

  18. Slide 18: CFT7455 Profile Supports Multiple Opportunities across MM Landscape

    CFT7455 Profile Supports Multiple Opportunities across MM Landscape © 2024 C4 Therapeutics, Inc. CFT7455 + Dexamethasone Data Potential Opportunity Accelerated Approval in Multi-Refractory MM Potential Development Path Post-Transplant Maintenance Study + PI Studies + Anti-CD38 Studies + BCMA BiTE St

  19. Slide 19: CFT1946 Targeting BRAF V600X Melanoma, CRC & NSCLC

    CFT1946 Targeting BRAF V600X Melanoma, Colorectal (CRC) & Non-Small Cell Lung Cancer (NSCLC)

  20. Slide 20: CFT1946 has the Potential to Overcome Resistance Mechanisms Seen with Inhibition

    CFT1946 has the Potential to Overcome Resistance Mechanisms Seen with Inhibition in BRAF V600X Cancers © 2024 C4 Therapeutics, Inc. • Orally bioavailable • Potent and selective against BRAF V600X mutant targets while sparing wildtype activity • Preclinical activity in settings of resistance to BRAF

  21. Slide 21: BRAF V600X Degrader Advantages Vary by Indication and May Require Combination

    BRAF V600X Degrader Advantages Vary by Indication and May Require Combination © 2024 C4 Therapeutics, Inc. Non-small cell lung cancer (NSCLC); Colorectal Cancer (CRC) MEK ERK GENE ON UNCONTROLLED CELL PROLIFERATION wtRAF RAS BRAF V600X CFT1946 in combination with trametinib/MEK inhibitor may increas

  22. Slide 22: CFT1946 has the Potential to Address Multiple Tumor Types with BRAF V600X Mutations

    CFT1946 has the Potential to Address Multiple Tumor Types with BRAF V600X Mutations Where BRAF Inhibitors are Insufficient © 2024 C4 Therapeutics, Inc. 22 BRAF V600X Mutation Rate 2023 U.S. Incidence of BRAF V600X Patients4 Approved BRAF Inhibitors BRAF Inhibitor Regimen mPFS5 Melanoma ~35% ~35,000

  23. Slide 23: CFT1946 is More Efficacious than SOC in CRC & NSCLC Models

    0 500 1000 1500 0 7 14 21 T u m o r V o lu m e ( m m 3 ) Treatment time (days) CFT1946 is More Efficacious than SOC in CRC & NSCLC BRAF V600X Xenograft Models and in a Melanoma PDX BRAF Inhibitor Resistance Model CRC CFT1946 as a monotherapy and + cetuximab shows enhanced responses Oral administrati

  24. Slide 24: CFT1946 is Active in Preclinical Metastatic Melanoma CNS Models

    CFT1946 is Active in Preclinical Metastatic Melanoma CNS Models © 2024 C4 Therapeutics, Inc. 24 CFT1946 Reduces CNS Tumor Burden in Metastatic Melanoma CNS Model 0 30 60 90 120 0 Days of treatment P h o to n s /s e c ( e 1 0 ) Vehicle Encorafenib, 35 mg/kg CFT-1946, 10 mg/kg CFT-1946, 30 mg/kg 0.5 1

  25. Slide 25: CFT1946 Phase 1/2 Dose Escalation Trial Continues to Progress

    CFT1946 Phase 1/2 Dose Escalation Trial Continues to Progress Twice a day (BID); standard of care (SoC); Non-small cell lung cancer (NSCLC); Colorectal Cancer (CRC);l Anaplastic thyroid cancer (ATC); Central nervous system (CNS) 1. NCT05668585. www.clinicaltrials.gov. Accessed January 9, 2024. 2. CF

  26. Slide 26: Plasma Exposure of CFT1946 Increased Roughly Proportionally with Dose

    Plasma Exposure of CFT1946 Increased Roughly Proportionally with Dose © 2024 C4 Therapeutics, Inc. Pharmacokinetic (PK) Source: C4T data on file as of 11/9/2023 Cycle 1 Day 1 Cycle 1 Day 15 0 4 8 12 10 100 1000 Time (h) P la s m a P K ( n g /m L ) 0 4 8 12 10 100 1000 Time (h) P la s m a P K ( n g /

  27. Slide 27: CFT1946 Degrades BRAF V600E in Melanoma Tissue and Decreases VAF in ctDNA

    α-BRAF (BRAF V600E) α-pERK1/2 B a se lin e C 1 D 1 5 At 80 mg, CFT1946 Degrades BRAF V600E in Melanoma Tissue and Demonstrates Rapid Decrease of BRAF V600E VAF in ctDNA 0 10 20 30 0 5 10 15 20 Melanoma Days V A F ( % ) BRAF V600E LOD Patient also demonstrated 7% decrease in tumor volume in correlati

  28. Slide 28: CFT8919 Targeting EGFR L858R Non-Small Cell Lung Cancer

    CFT8919 Targeting EGFR L858R Non-Small Cell Lung Cancer (NSCLC)

  29. Slide 29: Potential for CFT8919 to Improve Outcomes for NSCLC Patients with EGFR L858R Mutations

    Potential for CFT8919 to Improve Outcomes for NSCLC Patients with EGFR L858R Mutations © 2024 C4 Therapeutics, Inc. 29 Market Size • ~$6B approved EGFR inhibitor market 1 Osimertinib and other inhibitors provide suboptimal responses in L858R mutant NSCLC compared to other mutations of NSCLC Strong R

  30. Slide 30: CFT8919 is a Potent, Oral, Allosteric, Mutant-selective Degrader of EGFR L858R

    CFT8919 is a Potent, Oral, Allosteric, Mutant-selective Degrader of EGFR L858R 30 • CFT8919 exploits allosteric binding site, close to L858R activating mutation Allosteric binding avoids resistance mutations, wild-type activity, and is combinable with orthosteric inhibitors CFT8919 © 2024 C4 Therape

  31. Slide 31: 2024 Milestones: Advancing High-potential Programs

    2024 Milestones: Advancing High-potential Programs © 2024 C4 Therapeutics, Inc. 31 Multiple Value Inflection Points over Next 12 Months with Sufficient Runway (into 20271) Beyond These Milestones CFT7455 IKZF1/3 • 2H 2024: Present updated data from Phase 1 dose escalation +dex trial in R/R MM • 2H 2

C4 Therapeutics — Investor Presentation (January 2024) on 6ix